Drugs / Adacel
Adacel
also known as
Infanrix · Daptacel · Tdap vaccine · Infanrix-IPV/Hib · Adacel (Tdap) · Boostrix · Diphtheria and Tetanus Toxoids and Acellular Pertussis · DTaP(5) · +6 more
Trials 42 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03498300 | May 2018 → Apr 2019 | pertussis, pregnancy disorder | Mahidol University | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07492303 | Apr → Jul 2026 overdue | diphtheria, pertussis, tetanus | Changchun BCHT Biotechnology Co. | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01689324 | Sep → Nov 2012 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03562377 | Jul 2018 → Sep 2019 | atopic eczema | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01445743 | Sep 2011 → Aug 2012 | pregnancy disorder | Hospital Universitario Dr. Jose E. Gonzalez | Completed | No outcome recorded |
| Phase 2 | NCT00355121 | Oct 2006 → Jun 2009 | diphtheria, meningococcal meningitis, pertussis, poliomyelitis +1 | Sanofi | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06494475 | Dec 2024 → Jun 2025 overdue | group B streptococcal infection | Minervax ApS | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT04142983 | Feb 2020 → Nov 2021 | tetanus | GCAM Inc. | Completed | No outcome recorded |
| Phase 319 trials | ||||||
| Phase 3 | NCT02096263 | Apr 2014 → Feb 2015 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, poliomyelitis +1 | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01993173 | Nov 2013 → Feb 2014 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01346293 | Apr 2011 → May 2013 | diphtheria, measles, pertussis, poliomyelitis +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01000974 | Jun 2010 → Nov 2011 | haemophilus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01040052 | Dec 2009 → Feb 2010 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00988884 | Oct 2009 → Feb 2011 | human papilloma virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00696423 | Jun → Jul 2008 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00614614 | Feb 2008 → Jul 2009 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00518180 | Jul 2007 → Apr 2008 | human papilloma virus infection, meningococcal meningitis, pertussis, tetanus | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT00463437 | Apr 2007 → Jan 2008 | diphtheria, hepatitis B virus infection, pneumococcal infection, poliomyelitis +1 | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00412854 | Jan → Jun 2007 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00346073 | Jul 2006 → Mar 2007 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00325130 | Apr 2006 → Apr 2007 | diphtheria, meningitis, neoplasm, pertussis +1 | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00258908 | Nov 2005 → Aug 2006 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00255047 | Nov 2005 → Jul 2008 | diphtheria, pertussis, poliomyelitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00258895 | Mar 2005 → Dec 2006 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00197236 | Nov 2003 → Dec 2007 | hepatitis A virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00662870 | May 2001 → Jan 2004 | diphtheria, haemophilus infectious disease, pertussis, poliomyelitis +1 | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00984295 | Jun 2000 → Oct 2001 | chickenpox, measles, mumps infectious disease, rubella | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 414 trials | ||||||
| Phase 4 | NCT06803524 | May 2025 → Mar 2026 overdue | pertussis | Mahidol University | Recruiting | No outcome recorded |
| Phase 4 | NCT04543669 | Jul → Sep 2017 | pertussis | Dalhousie University | Completed | No outcome recorded |
| Phase 4 | NCT01711645 | Oct 2012 → Aug 2015 | diphtheria, pertussis, tetanus | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 4 | NCT01439165 | Nov 2011 → Dec 2015 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT01311557 | Mar → Nov 2011 | diphtheria, pertussis, tetanus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01094171 | Dec 2010 → Oct 2012 | poliomyelitis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT01137435 | Jun 2010 → Mar 2016 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT00457249 | Mar 2007 → Sep 2008 | diphtheria, pertussis, tetanus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00347958 | Aug 2006 → Feb 2008 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT00336115 | Jul 2006 → May 2008 | pertussis | Queen Elizabeth II Health Sciences Centre | Unknown | No outcome recorded |
| Phase 4 | NCT00319553 | May 2006 → Oct 2008 | diphtheria, pertussis, tetanus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00289913 | Apr 2006 → Jun 2010 | hepatitis A virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT00802867 | Feb 2004 → Jun 2005 | diphtheria, haemophilus infectious disease, pertussis, poliomyelitis +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT00544271 | May 2003 → Jan 2004 | diphtheria, tetanus | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00482781 | Sep 2000 → Sep 2004 | infantile apnea | American SIDS Institute | Completed | No outcome recorded |
Also used as a comparator or background therapy in 18 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02587520 Comparator | Oct 2015 → Feb 2017 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06015308 Background | Oct 2023 → Oct 2025 | atopic eczema | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT02199691 Comparator | Jul 2014 → Oct 2015 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00993447 Comparator | Oct 2009 → Sep 2011 | Dengue hemorrhagic fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00729001 Background | Nov 2000 → Sep 2002 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 310 trials | ||||||
| Phase 3 | NCT07160244 Background | Aug 2025 → Nov 2028 expected | — | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT02640703 Comparator | Mar 2015 → Dec 2016 | — | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 3 | NCT01627561 Comparator | Oct 2012 → Apr 2014 | human papilloma virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01642589 Comparator | Jul 2012 → Jan 2013 | meningitis, meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01337167 Background | Apr 2011 → May 2013 | bacterial infectious disease, viral infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01171963 Background | Aug 2010 → May 2012 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00990080 Comparator | May → Jul 2010 | — | Dalhousie University | Completed | No outcome recorded |
| Phase 3 | NCT01003431 Comparator | Dec 2009 → Aug 2010 | Rotavirus infection, diphtheria, pertussis, tetanus | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 3 | NCT00489970 Comparator | Jun 2007 → Sep 2011 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00148941 Comparator | Jan 2005 → Nov 2006 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT05264662 Comparator | Mar 2022 → Mar 2025 | — | Farzanah Laher | Completed | No outcome recorded |
| Phase 4 | NCT02002156 Background | Jun 2014 → Aug 2016 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 4 | NCT00712959 Comparator | Jun 2008 → Sep 2009 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 62 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adacel | “This is a single site, prospective study involving only one intervention, receipt of a single 0.5 mL intramuscular (IM) dose of Adacel (Tetanus toxoid, reduced diphtheria...” NCT01711645 ↗23“Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Adacel™ vaccine administered intramuscularly in the deltoid region of the...” NCT00346073 ↗ “Participants will receive Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap - Adacel®)” NCT01642589 ↗ “Participants randomized to receive a repeat dose of Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine (Adacel®)” NCT01439165 ↗ “Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan” NCT00258908 ↗ “Healthy participants aged 10-18 years received Adacel®.” NCT02587520 ↗ |
| Known as | Adacel (Tdap) | “Adacel® (Tdap)” NCT02199691 ↗ |
| Known as | Boostrix | “Boostrix (tetanus, diphtheria, and acellular pertussis” NCT06015308 ↗ |
| Known as | Daptacel | “The study was designed to compare the safety and immunogenicity of DTap-IPV with DAPTACEL® + IPOL® as the 5th dose booster” NCT01346293 ↗8“diphtheria, tetanus, 5-component acellular pertussis vaccine [DTaP(5); Daptacel]” PMID 19117896 ↗ Jan 2009 “Menactra® vaccine and DAPTACEL® vaccine” NCT00355121 ↗ “DAPTACEL®” NCT00662870 ↗ |
| Known as | Diphtheria and Tetanus Toxoids and Acellular Pertussis | “Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)” NCT00802867 ↗ |
| Known as | DTaP(5) | “diphtheria, tetanus, 5-component acellular pertussis vaccine [DTaP(5); Daptacel]” PMID 19117896 ↗ Jan 2009 |
| Known as | Infanrix | “Subjects received Infanrix co-administered with ActHIB at Day 0, followed by one dose of Havix at Day 30” NCT00197236 ↗ |
| Known as | Infanrix---IPV---Hib, GlaxoSmithKline | “Infanrix™---IPV---Hib, GlaxoSmithKline” NCT02002156 ↗ |
| Known as | Infanrix-IPV/Hib | “Infanrix™-IPV/Hib at 2 months of age followed by Pediacel® at 4 and 6 months.” NCT00990080 ↗ |
| Known as | InfanrixTM | “Subjects received 3 primary doses of PoliorixTM and InfanrixTM vaccines at 3, 4.5 and 6 months of age.” NCT01094171 ↗ |
| Known as | Tdap vaccine | “tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (ADACEL®, Tdap vaccine)” NCT01689324 ↗ |
| Known as | Tdap5 | “This study was conducted to determine whether Tdap5 (Adacel), which is licensed for use in children beginning at 11 years of age, is as safe and immunogenic in 10-year-olds as...” PMID 25230939 ↗ Sep 2014 |
| Known as | Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00993447 ↗ |
| Known as | Tetanus-diphtheria-acellular pertussis (Tdap) vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00347958 ↗ |
| Known as | Tripedia | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00984295 ↗ |
| Modality | Vaccine | “Infanrix vaccine” NCT00148941 ↗ |
| Route | Intramuscular | “1 intramuscular injection” NCT00197236 ↗ |